Viewing Study NCT00334295


Ignite Creation Date: 2025-12-24 @ 1:58 PM
Ignite Modification Date: 2026-02-03 @ 4:28 AM
Study NCT ID: NCT00334295
Status: COMPLETED
Last Update Posted: 2012-07-31
First Post: 2006-06-05
Is Gene Therapy: True
Has Adverse Events: True

Brief Title: Fulvestrant for the Treatment of Recurrent or Metastatic Endometrial Carcinoma.
Sponsor: AstraZeneca
Organization:

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Endometrial Carcinoma View
Keywords:

Keywords

Keyword Brief Keyword Text View
None Recurrent or metastatic endometrial carcinoma View